scholarly journals Effects of ‎tamoxifen on the reproductive system of female breast cancer patients: an ultrasound-based cohort study

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 102
Author(s):  
Ghasak Kais Abd-Alhussain‎ ◽  
Mohammed Qasim Yahya Mal-Allah Alatrakji‎ ◽  
Wieeam Abdulfattah Saleh‎ ◽  
Hayder Adnan Fawzi ◽  
Aqeel‎ Shaker Mahmood‎
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Side Effects ◽  
Endometrial Thickness ◽  
Menopausal Status ◽  
Hormonal Treatment ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Er Positive ◽  
Adjuvant Hormonal Treatment

Background: Tamoxifen (TMX) is regarded as standard treatment for breast cancer (BC) patients‎. In recent years, several studies have reported gynecological side effects and due to TMX's estrogenic effects. Here, we evaluate the side effects of TMX on the ‎endometrium and ovaries of female BC patients. Methods: This was an ultrasound-based cohort study conducted in three oncology centers in Baghdad, Iraq. A total of ‎‎255 female patients were included, 140 premenopausal (PreM) and 115 postmenopausal (PostM), with estrogen receptor (ER)-positive BC using TMX adjuvant hormonal treatment for at least three months after surgery and adjuvant ‎chemo/radiotherapy.‎ Ultrasound (US) on the endometrium and ovaries of the women following ‎BC surgery/chemotherapy (baseline) and at 3, 6, 12, and 24 months following was performed‎. Data collected included age, menopausal status, co-morbid chronic illness and medications, including duration of TMX treatment. Results: Presence of ovarian cyst was significantly higher in the PreM ‎compared to PostM ‎women, while there were no significant differences for other gynecological findings.‎ At ‎baseline, endometrial thickness (ET) was significantly higher in the PreM compared to the PostM women. In both groups, women with increased ET became more frequent from baseline to 3 ‎months, from 3 to 6 ‎months, from 6 to 12 months, and from 12 ‎ to 24 months. At all time periods, ‎women with increased ET was ‎significantly higher in the PostM compared PreM women, resulting ‎in a risk of ET increase by 6 folds (ranging from 3 – ‎‎11 folds) ‎in PostM compared to PreM women. Conclusions: Longer duration of TMX is associated with increased ET. Duration of TMX did not appear to increase the risk of various gynecological outcomes, for example endometrial cancer rate was low. Finally, there was an increase in ET, which appeared to be six-folds higher in PostM compared to PreM women.‎

scholarly journals Risk of major autoimmune diseases in female breast cancer patients: A nationwide, population-based cohort study

PLoS ONE ◽  
2019 ◽  
Vol 14 (9) ◽  
pp. e0222860 ◽  
Author(s):  
Hsin-Hua Chen ◽  
Ching-Heng Lin ◽  
Der-Yuan Chen ◽  
Wen-Cheng Chao ◽  
Yi-Hsing Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Autoimmune Diseases ◽  
Cancer Patients ◽  
Population Based ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Female Breast

scholarly journals Expression of Insulin Receptor and c-MET Is Associated with Clinicopathologic Characteristics and Molecular Subtypes in Premenopausal Breast Cancer Patients

2020 ◽  
Vol 10 (5) ◽  
pp. 1614
Author(s):  
Nehad M. Ayoub ◽  
Rami J. Yaghan ◽  
Alia H. Al-Mohtaseb ◽  
Najla Aldaoud ◽  
Ismail I. Matalka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Insulin Receptor ◽  
Cancer Patients ◽  
Molecular Subtypes ◽  
Menopausal Status ◽  
Breast Cancer Patients ◽  
Clinicopathologic Characteristics ◽  
Premenopausal Breast Cancer ◽  
Er Positive ◽  
Premenopausal Patients

Receptor Tyrosine Kinases (RTKs) represent a class of transmembrane receptors known to play an important role in cancer development and progression. In this study, the expression of insulin receptor (IR) and the hepatocyte growth factor receptor (c-MET) was examined in breast cancer patients. Immunohistochemistry for IR and c-MET was performed on 71 cases of invasive breast cancer and expression scores were correlated with clinicopathologic characteristics and molecular subtypes and further stratified based on a menopausal status. Expression of IR was significantly associated with the tumor grade (p = 0.017) and estrogen receptor (ER) expression (p = 0.015). There was a significant positive correlation between IR and c-MET expression scores (rho = 0.458, p < 0.001). Among premenopausal cases, IR scores were significantly higher in patients with grade I/II disease (p = 0.025), ER-positive (p = 0.030), and progesterone receptor (PR)-positive carcinoma (p = 0.015). c-MET expression scores were significantly higher among premenopausal patients with ER-positive (p = 0.007) and PR-positive carcinoma (p = 0.024). IR expression scores were significantly different among molecular subtypes for all patients (p = 0.006) and among premenopausal cases (p = 0.035). c-MET expression was statistically different among molecular subtypes for premenopausal patients (p = 0.019). Survival analysis revealed that the expression status of IR and c-MET was not associated with overall survival. Our findings support a favorable prognostic value for IR and c-MET expression in premenopausal breast cancer patients.

Weight gain after adjuvant treatment in breast cancer patients in Istanbul, Turkey

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11620-e11620
Author(s):  
N. S. Turhal ◽  
N. Yurt ◽  
G. Yurtseven ◽  
D. Cabuk ◽  
M. Teomete ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Weight Gain ◽  
Cancer Patients ◽  
Educational Level ◽  
Menopausal Status ◽  
Hormonal Treatment ◽  
Underlying Disease ◽  
Breast Cancer Patients ◽  
Before And After ◽  
Similar Weight

e11620 Background: Weight gain is a common and unwanted result of chemotherapy. We wanted to find out how much weight Turkish beast cancer patients gains after chemotherapy and whether it lasts afterwards. Methods: 183 breast cancer patients who underwent a curative resection and received adjuvant chemotherapy afterwards in a private clinic between 1998 and 2007 are studied. Their weight before and after chemotherapy as well as their weight more than a year after chemotherapy is recorded together with their educational level, menopausal status, the type of chemotherapy or hormonal treatment, stage of disease, marital status, occupation and the underlying diseases. Results: Median age of patients is 53 and 72% is in menopause. Educational level is equally distributed for primary education (26%), High school (30%) and University and above (32%). Majority is (76%) married with two children (43%) and house wife (50%). Family history of any cancer is high (33%). Most of the patients had stage II cancer (57%), received anthracycline± taxane based chemotherapy (97%) and has no underlying disease (67%). The majority also does not smoke (72%) or drink alcohol (93%). Mean weight before the chemotherapy was 69.1 and increased to 70.8 upon completion of chemotherapy (p= 0.000) and 72 kg. more than a year after completion of chemotherapy (p=0.000). The other parameters including hormonal treatment, menopause, educational level and smoking do not have any effect on this weight increase. The all groups had similar weight gain with chemotherapy. Conclusions: Although upon starting the study we expected more, we confirmed some amount of weight gain with chemotherapy in Turkish patients and that gain is seen all across various social groups. The doctors should inform their patients of this change and precaution them toward this unwanted consequence. No significant financial relationships to disclose.

scholarly journals Tamoxifen treatment and its outcome in breast cancer patients at a hospital-based cancer registry in Kerala

2020 ◽  
Vol 8 (10) ◽  
pp. 3665
Author(s):  
Reema A. Thomas ◽  
Catherin Nisha
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Patients ◽  
Cancer Registry ◽  
Endometrial Thickness ◽  
Tamoxifen Treatment ◽  
Accurate Information ◽  
Breast Cancer Patients ◽  
Study Objective ◽  
Systemic Adjuvant Therapy

Background: Endocrine therapy for breast cancer is directed at reducing oestrogen synthesis or alternatively blocking oestrogen receptors (ER) in tumour-sensitive tumors. Despite side effects, the use of systemic adjuvant therapy after local management of breast cancer substantially improves survival and reduces the risk of relapse. The study objective was to assess the recurrence of breast cancer and the complications seen in breast cancer patients on tamoxifen therapy at a hospital-based cancer registry, Thrissur, Kerala.Methods: After obtaining institutional ethical clearance, included 75 patients of histologically diagnosed breast carcinoma currently on tamoxifen, diagnosed in the year of 2016. Data was obtained from the patient files and by personal intimation.Results: Of the 75 patients on tamoxifen, four (5.33%) patients had history of recurrence. 22.6% of patients on tamoxifen were noted to have increased endometrial thickness. Other side effects noted were weight gain, TIA, bone pain and vaginal discharge.Conclusions: It was found that the recurrence rate at three years for the study population was 5.33%. More studies from developing countries, with larger sample size and clinical trials will give us more accurate information regarding the efficacy of the drug.

scholarly journals Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients’ Population

2020 ◽  
Vol 17 (10) ◽  
pp. 3692
Author(s):  
Kristina Bojanic ◽  
Lucija Kuna ◽  
Ines Bilic Curcic ◽  
Jasenka Wagner ◽  
Robert Smolic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Critical Role ◽  
Study Groups ◽  
Breast Cancer Patients ◽  
Mineral Density ◽  
Metabolizing Enzymes ◽  
Genes Encoding ◽  
Er Positive ◽  
Hormonal Adjuvant Therapy

Single nucleotide polymorphism (SNP) in genes encoding drug-metabolizing enzymes (DME) could have a critical role in individual responses to anastrozole. Frequency of CYP3A4*1B, CYP3A5*3 and UGT1A4*2 SNPs in 126 Croatian breast cancer (BC) patients and possible association with anastrozole-induced undesirable side effects were analyzed. Eighty-two postmenopausal patients with estrogen receptor (ER)-positive BC treated with anastrozole and 44 postmenopausal ER-positive BC patients before hormonal adjuvant therapy were included in the study. Genomic DNA was genotyped by TaqMan Real-Time PCR. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry. The homozygotes for the variant G allele of CYP3A5*3 were predominant (88%), and the homozygotes for the reference A allele were not detected. While homozygotes for the variant G allele of CYP3A4*1B were not detected, predominantly wild type homozygotes for A allele (94%) were present. CYP3A4*1B and CYP3A5*3 SNPs were in 84.3% linkage disequilibrium (D’ = 0.843) and 95.1% (D’ = 0.951) in group treated with anastrozole and w/o treatment, respectively. Homozygotes for the A allele of UGT1A4*2 were not detected in our study groups. Although the variant CYP3A5*3 allele, which might result in poor metabolizer phenotype and more pronounced side effects, was predominant, significant association with BMD changes induced by anastrozole were not confirmed.

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

1992 ◽  
Vol 10 (8) ◽  
pp. 1284-1291 ◽  
Author(s):  
P M Ravdin ◽  
S Green ◽  
T M Dorr ◽  
W L McGuire ◽  
C Fabian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Treatment Failure ◽  
Menopausal Status ◽  
Prognostic Significance ◽  
Breast Cancer Patients ◽  
Time To Treatment ◽  
Time To Treatment Failure ◽  
Er Positive ◽  
Positive Breast Cancer

PURPOSE Southwest Oncology Group (SWOG) protocol 8228 is a prospective trial designed to investigate the prognostic significance of progesterone receptor (PgR) levels in estrogen receptor (ER)-positive breast cancer patients who were treated with tamoxifen. This study was undertaken because the value of PgR measurements in advanced breast cancer had been assessed previously only in studies that were small, retrospective, or included heterogeneously treated patients. METHODS Receptor assays were performed only in the laboratories that met strict quality control guidelines. Of the 398 patients entered, 342 patients were eligible and assessable for the study end points of objective clinical response, time to treatment failure, and overall survival. RESULTS Multivariate analysis shows that elevated PgR levels significantly and independently correlated with increased probability of response to tamoxifen, longer time to treatment failure, and longer overall survival. Overall response rate (defined as complete response [CR], partial response [PR], or stable disease [SD] for greater than 6 months) in this trial was 54%. Response rates to tamoxifen were 43%, 53%, and 61% in subsets of patients with less than 10, 10 to 99, and more than 100 fmol/mg PgR, respectively. Exploratory subset analysis using PgR and other prognostic variables identified ER-positive patient subsets with response rates to tamoxifen ranging from 24% (premenopausal patients) to 86% (postmenopausal patients with ER greater than 38 and PgR greater than 329 fmol/mg). No groups of ER-positive patients were identified who had such a low response rate as to absolutely preclude considering the use of tamoxifen. Multivariate analysis showed the independent, statistically significant predictors were: for response to tamoxifen, menopausal status, PgR, and ER; for time to treatment failure, menopausal status, disease-free interval (DFI), PgR, and ER; and for overall survival DFI, PgR, ER, site of disease, and history of adjuvant therapy. CONCLUSION We conclude that knowledge of PgR levels together with other clinical information can improve the pretreatment assessment of ER-positive breast cancer patients with metastatic disease.

scholarly journals Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study

2020 ◽  
pp. FSO617
Author(s):  
Valentina Zanuso ◽  
Vittorio Fregoni ◽  
Lorenzo Gervaso
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Side Effects ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Kaplan Meier ◽  
Chemotherapy Side Effects ◽  
Dose Reductions

Aim: Breast cancer patients over the age of 65 are more likely to suffer chemotherapy side effects, with premature discontinuation, which negatively affects survival. Methods: We conducted a retrospective cohort study enrolling breast cancer patients; dose reductions or interruptions of chemotherapy have been collected, as well as side effects. Progression-free survival was determined by Kaplan–Meier and evaluated for its association with reduction/suspension. The study included 128 women (median age: 71). Results: Nineteen patients experienced cardiotoxicity, while dosage of chemotherapy was reduced in 23 patients (18.0%), and 14 (10.9%) had premature interruptions. Dose reduction/interruptions were associated with numerically worse progression-free survival (78.2 vs 94.8 months; p = 0.10). Conclusion: Reduction/discontinuation of chemotherapy due to side effects affected nearly 30% of our population, potentially worsening outcomes.

Sign in / Sign up

Export Citation Format

Share Document